US FDA approves inhaled treprostinil (Tyvaso) for treatment of pulmonary hypertension associated with interstitial lung disease

Approval of Tyvaso to improve exercise ability was based on data from the INCREASE trial, in which it was associated with benefits across several key patient subgroups. It was first approved in the US in 2009 for the treatment of pulmonary arterial hypertension.

Source:

Biospace Inc.